You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

 

Online download statistics by month:

Online download statistics by month: March 2021 to December 2025

AbstractFullPdf
Mar 2021594592304
Apr 2021378378133
May 202123223278
Jun 202120120163
Jul 202117917960
Aug 202116316350
Sep 202114314366
Oct 202119019069
Nov 202123923961
Dec 202113613845
Jan 202213013763
Feb 202211112169
Mar 2022173188103
Apr 202214916070
May 202213214481
Jun 202213715063
Jul 202211712660
Aug 202213014049
Sep 202210511378
Oct 202210210653
Nov 202212012264
Dec 202210010354
Jan 2023919130
Feb 202314414457
Mar 2023949644
Apr 2023888834
May 2023868930
Jun 202310510541
Jul 2023919128
Aug 2023717128
Sep 2023696938
Oct 2023999941
Nov 202312512649
Dec 2023858730
Jan 2024929930
Feb 202410710951
Mar 2024868949
Apr 202413313779
May 202410610860
Jun 2024868547
Jul 2024919238
Aug 2024738140
Sep 2024838542
Oct 202410711357
Nov 20249710143
Dec 202410811247
Jan 202512212771
Feb 2025828437
Mar 202510810877
Apr 202513813963
May 2025868655
Jun 2025424436
Jul 2025110
Sep 2025220
Dec 2025100
Total686070233108